[go: up one dir, main page]

AR043966A1 - DERIVATIVES OF 4- (2-Phenyloxyphenyl) - PIPERIDINE OR 1,2,3,6-TETRAHYDROPIRIDINE AS INHIBITORS OF SEROTONINE RECAPTATION - Google Patents

DERIVATIVES OF 4- (2-Phenyloxyphenyl) - PIPERIDINE OR 1,2,3,6-TETRAHYDROPIRIDINE AS INHIBITORS OF SEROTONINE RECAPTATION

Info

Publication number
AR043966A1
AR043966A1 ARP040101132A ARP040101132A AR043966A1 AR 043966 A1 AR043966 A1 AR 043966A1 AR P040101132 A ARP040101132 A AR P040101132A AR P040101132 A ARP040101132 A AR P040101132A AR 043966 A1 AR043966 A1 AR 043966A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
hydrogen
ilo
independently selected
Prior art date
Application number
ARP040101132A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36701494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043966(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR043966A1 publication Critical patent/AR043966A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Los compuestos son útiles para el tratamiento de trastornos afectivos, incluyendo la depresión, trastornos de ansiedad, incluyendo el trastorno de ansiedad general, trastorno de pánico y trastorno obsesivo compulsivo. Reivindicación 1: Un compuesto representado por la fórmula general (1), en la cual: la línea de puntos indica una unión simple o una unión doble; R1, R2, R3, R4, R5 se seleccionan independientemente de hidrógeno, halógeno, ciano, alqu(en/in)ilo C1-6, alqu(en/in)iloxi C1-6, alqu(en/in)ilsulfanilo C1-6, hidroxi, hidroxi-alqu(en/in)ilo C1-6, halo-alqu(en/in)ilo C1-6, halo-alqu(en/in)iloxi C1-6, o NRxRy en donde Rx y Ry se seleccionan independientemente de hidrógeno, alqu(en/in)ilo C1-6, ciano-alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il-(C3-8)-alqu(en/in)ilo (C1-6), o NRzRw-alqu(en/in)ilo C1-6, en donde Rz y Rw se seleccionan independientemente de hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, o cicloalqu(en)il-(C3-8)-alqu(en/in)ilo (C1-6); o Rx y Ry junto con el nitrógeno al que están unidos forman un anillo de 3-7 miembros que opcionalmente contiene un heteroátomo adicional; o R2 y R3 forman juntos un heterociclo fusionado al anillo de fenilo seleccionado de la fórmula (2); R1, R4, R5 son como se definió anteriormente; R6, R7, R8, R9 se seleccionan independientemente de hidrógeno, halógeno, alqu(en/in)ilo C1-6, alqu(en/in)iloxi-C1-6, alqu(en/in)ilsulfanilo C1-6, hidroxi, hidroxi-alqu(en/in)ilo C1-6, halo-alqu(en/in)ilo C1-6, halo-alqu(en/in)iloxi C1-6, o NRxRy en donde Rx y Ry se seleccionan independientemente de hidrógeno, alqu(en/in)ilo C1-6, ciano-alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il-(C3-8)-alqu(en/in)ilo (C1-6), o NRzRw-alqu(en/in)ilo C1-6, en donde Rz y Rw se seleccionan independientemente de hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, o cicloalqu(en)il-(C3-8)-alqu(en/in)ilo (C1-6); o Rx y Ry junto con el nitrógeno al que están unidos forman un anillo de 3-7 miembros que opcionalmente contiene un heteroátomo adicional; siempre al menos uno de R1, R2, R3, R4, R5, R6, R7, R8, y R9 sea diferente de hidrógeno; o una sal del mismo.The compounds are useful for the treatment of affective disorders, including depression, anxiety disorders, including general anxiety disorder, panic disorder and obsessive compulsive disorder. Claim 1: A compound represented by the general formula (1), in which: the dotted line indicates a single bond or a double bond; R1, R2, R3, R4, R5 are independently selected from hydrogen, halogen, cyano, C1-6 alkyl (en / in), C1-6 alkyloxy, C1-6 alkylsulfanyl 6, hydroxy, hydroxy-alkyl (en / in) C1-6 yl, halo-alkyl (en / in) C1-6 yl, halo-alkyl (en / in) C1-6 yloxy, or NRxRy wherein Rx and Ry are independently selected from hydrogen, alkyl (en / in) C1-6 yl, cyano-alkyl (en / in) C1-6 yl, cycloalkyl (en) C3-8yl, cycloalkyl (en) il- (C3-8) -alk (in / in) ilo (C1-6), or NRzRw-alky (in / in) ilo C1-6, wherein Rz and Rw are independently selected from hydrogen, alky (in / in) ilo C1-6, C3-8 cycloalkyl (en) or cycloalkyl (en) yl- (C3-8) -alkyl (en / in) yl (C1-6); or Rx and Ry together with the nitrogen to which they are attached form a 3-7 membered ring that optionally contains an additional heteroatom; or R2 and R3 together form a heterocycle fused to the phenyl ring selected from the formula (2); R1, R4, R5 are as defined above; R6, R7, R8, R9 are independently selected from hydrogen, halogen, C1-6 alkyl (en / in), C1-6 alkyloxy, C1-6 alkylsulfanyl, hydroxy , hydroxy-alkyl (en / in) C1-6 yl, halo-alkyl (en / in) C1-6 yl, halo-alkyl (en / in) C1-6 yloxy, or NRxRy wherein Rx and Ry are independently selected hydrogen, alkyl (en / in) C1-6 yl, cyano-alkyl (en / in) C1-6 yl, cycloalkyl (en) C3-8yl, cycloalkyl (en) yl- (C3-8) -alkyl ( in / in) ilo (C1-6), or NRzRw-alky (in / in) ilo C1-6, where Rz and Rw are independently selected from hydrogen, alky (in / in) ilo C1-6, cycloalk (in ) C3-8 yl, or cycloalkyl (en) yl- (C3-8) -alkyl (en / in) yl (C1-6); or Rx and Ry together with the nitrogen to which they are attached form a 3-7 membered ring that optionally contains an additional heteroatom; always at least one of R1, R2, R3, R4, R5, R6, R7, R8, and R9 is different from hydrogen; or a salt thereof.

ARP040101132A 2003-04-04 2004-04-02 DERIVATIVES OF 4- (2-Phenyloxyphenyl) - PIPERIDINE OR 1,2,3,6-TETRAHYDROPIRIDINE AS INHIBITORS OF SEROTONINE RECAPTATION AR043966A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200300519 2003-04-04

Publications (1)

Publication Number Publication Date
AR043966A1 true AR043966A1 (en) 2005-08-17

Family

ID=36701494

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101132A AR043966A1 (en) 2003-04-04 2004-04-02 DERIVATIVES OF 4- (2-Phenyloxyphenyl) - PIPERIDINE OR 1,2,3,6-TETRAHYDROPIRIDINE AS INHIBITORS OF SEROTONINE RECAPTATION

Country Status (8)

Country Link
KR (1) KR20050119682A (en)
CN (1) CN1767829A (en)
AR (1) AR043966A1 (en)
CL (1) CL2004000726A1 (en)
EA (1) EA009417B1 (en)
IS (1) IS7901A (en)
UA (1) UA81469C2 (en)
ZA (1) ZA200505031B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613347B (en) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 Amine compound and medical application thereof
DK2358676T3 (en) * 2008-11-14 2013-01-14 Theravance Inc Crystalline form of a 4- [2- (2-fluorophenoxymethyl) phenyl] -piperidine compound
CN104710345B (en) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 For preparing 4（2‑（4 aminomethyl phenyl sulfenyls））Compound, its preparation method and the application of Phenylpiperidine
CN105348204B (en) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1- heterocycles -2- (Heteroarylthio) benzene derivatives and its application method and purposes
CN105294554B (en) * 2015-11-18 2017-11-07 乳源瑶族自治县大众药品贸易有限公司 Phenylpiperazine derivatives and methods and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
SK4732002A3 (en) * 1999-10-13 2002-12-03 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors
UA81749C2 (en) * 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS

Also Published As

Publication number Publication date
UA81469C2 (en) 2008-01-10
CL2004000726A1 (en) 2005-05-20
KR20050119682A (en) 2005-12-21
IS7901A (en) 2005-06-20
EA200501580A1 (en) 2006-04-28
CN1767829A (en) 2006-05-03
ZA200505031B (en) 2006-09-27
EA009417B1 (en) 2007-12-28

Similar Documents

Publication Publication Date Title
ES2613538T3 (en) Arylamide derivatives as TTX-S blockers
MX2009008465A (en) 2-aminooxazolines as taar1 ligands.
ECSP099324A (en) NEW DERIVATIVES OF AMINOPIRIMIDINE AS PLK1 INHIBITORS
MY139750A (en) Cyclohexylamides as dopamine d3, d2 and 5ht1a antagonists
AR054024A1 (en) PIRIDINE DERIVATIVES -3- CARBOXAMIDE AS INVESTED AGONISTS OF CB1
AR073136A1 (en) PIRROL COMPOUNDS
ES2531056T3 (en) Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
CO6241119A2 (en) PIRIDO COMPOUNDS 2,3-D PIRIMIDINA-7-ONA AS PI3K-ALFA INHIBITORS FOR CANCER TREATMENT
AR061486A1 (en) DERIVATIVES OF 2-PIRAZINACARBOXAMIDA
AR085615A1 (en) USEFUL FLUOROPIRIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR082886A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ECSP099395A (en) NEW DERIVATIVES OF AMINO-NICOTINIC AND AMINO-ISONICOTINIC ACIDS
CO6160296A2 (en) BENZOAZEPIN-OXI-ACETIC ACID DERIVATIVES AS RECEPTOR AGONISTS ACTIVATED BY DELTA PEROXISONE PROLIFERATOR USED TO INCREASE HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL-CHOLESTEROL REDUCE LIPOPROTEIN-LOW DENSITY-COLESTEROL
NO20072632L (en) Oxadiazole derivatives as DGAT inhibitors
EA201071012A1 (en) DERIVATIVES OF AZETIDINE, METHOD OF THEIR RECOVERY AND USE OF THEM IN THERAPY
AR069480A1 (en) DERIVATIVES OF 2-AMINO-PYRIMIDINE
DK2197860T3 (en) Novel compounds as adenosine A1 receptor antagonists
PE20060583A1 (en) TIAZOLIL-DIHIDRO-INDAZOLES AS INHIBITORS OF PI3-KINASES
AR084913A1 (en) DERIVATIVES OF ARIL-BENZOCICLOALQUIL-AMIDA
AR050266A1 (en) DERIVATIVES OF BENCIL-TRIAZOLONA AS NON-NUCLEOSID INHIBITORS OF INVERSE TRANSCRIPT
NO20062617L (en) Use of glucosidase inhibitors for therapy of mucovisidosis
AR043964A1 (en) DERIVATIVES OF 4- (2-PHENYLSULPHANYL-PHENYL) 1,2,3,6-TETRAHYDROPIRIDINE AS ANHIBITORS OF SEROTONIN RECAPTATION
AR084606A1 (en) BIARIL-AMIDA DERIVATIVES
CO6400145A2 (en) DERIVATIVES OF 2-PIRIDIN-2-IL PIRAZOL-3 (2H) -ONA, ITS PREPARATION AND THERAPEUTIC APPLICATION
CO5700747A2 (en) NEW PIPERIDINS AS CHEMOQUINE MODULATORS (CCR)

Legal Events

Date Code Title Description
FB Suspension of granting procedure